Skip to Content

Jing Yang, Ph. D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Regular Member, Graduate Faculty, The Graduate School of Biomedical Sciences (GSBS), The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

My research study emphasis is on translating research results into better therapeutic targets in multiple myeloma. One of my research foci is to study the mechanism underlying the pathogenesis of myeloma bone disease. We have addressed this by investigating the ability of myeloma cells to enhance bone resorption and suppress bone formation by regulating the differentiation and activity of osteoblasts, osteoclasts, adipocytes, and other marrow stroma. Another one of my research foci is the interaction of myeloma cells with bone marrow microenvironment and the role of tumor microenvironment in chemotherapy resistance. These studies aim to provide novel and potential therapeutic targets and tools for the treatment myeloma and myeloma-associated bone disease.

Education & Training

Degree-Granting Education

2002 Xiangya Medical College, Central South University, Changsha, China, PHD, Molecular Biology
1994 Guangzhou Medical University, Guangzhou, China, MS, Tumor Biology
1991 Guangzhou University, Guangzhou, China, BS, Biology

Postgraduate Training

2004-2008 Research Fellowship, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
2004 Research Fellowship, Myeloma Institute of Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR


Institutional Committee Activities

Member, Faculty academic Review Committee, 2015-2018
Reviewer, INTErnal REview study SecTion, 2015
Reviewer, Endowed Fellowships for the MDACC Trainees, 2015

Honors and Awards

2009-2014 K99/R00, National Cancer Institute
2008-2010 ASH Scholar Fellowship Award, American Society of Hematology
2008 Brian D. Novis Research Award, International Myeloma Foundation
2007 ASH Travel Award, 49th American Society of Hematology
2006 Altana Pharma Publication Award, MD Anderson Cancer Center
2003-2004 National Nature Science Foundation of China, National Nature Science Foundation of China
2001 Scholarship of Central South University in China, Central South University in China
2001 Tan Jiazhen-Fudan University Life Science Award in China, Tan Jiazhen-Fudan University

Professional Memberships

American Association for Cancer Research
Member, 2001-present
Annual Postdoctoral Science Symposium, Houston, Texas
Judge and Internal Reviewer, 2015

Selected Publications

Peer-Reviewed Original Research Articles

1. Liu H, Liu Z, Du J, He J, Lin P, Amini B, Starbuck MW, Novane N, Shah JJ, Davis RE, Hou J, Gagel RF, Yang J. Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma. Sci Transl Med 8(353):353ra113, 8/2016. PMID: 27559096.
2. Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DL, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell 29(5):639-52, 5/2016. e-Pub 4/2016. PMID: 27132469.
3. Liu Z, Xu J, He J, Liu H, Lin P, Wan X, Navone NM, Tong Q, Kwak LW, Orlowski RZ, Yang J. Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. Oncotarget 6(33):34329-34341, 10/2015. PMID: 26455377.
4. Zhang M, He J, Liu Z, Lu Y, Zheng Y, Li H, Xu J, Liu H, Qian J, Orlowski RZ, Kwak LW, Yi Q, Yang J. Anti-β2-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. Oncotarget 6(11):8567-78, 4/2015. e-Pub 3/2015. PMID: 25895124.
5. He Z, He J, Liu Z, Xu J, Yi SF, Liu H, Yang J. MAPK11 in breast cancer cells enhances osteoclastogenesis and bone resorption. Biochimie 106:24-32, 11/2014. e-Pub 7/2014. PMCID: PMC4250302.
6. Liu Z, Xu J, He J, Zheng Y, Li H, Lu Y, Qian J, Lin P, Weber DM, Yang J, Yi Q. A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance. Blood 124(13):2061-71, 9/2014. e-Pub 7/2014. PMCID: PMC4186536.
7. Zhang M, Qian J, Lan Y, Lu Y, Li H, Hong B, Zheng Y, He J, Yang J, Yi Q. Anti-β2 M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity. Int J Cancer 135(5):1132-41, 9/2014. e-Pub 2/2014. PMID: 24474467.
8. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia 28(2):373-83, 2/2014. e-Pub 6/2013. PMCID: PMC3874423.
9. Gu D, Wang S, Kuiatse I, Wang H, He J, Dai Y, Jones RJ, Bjorklund CC, Yang J, Grant S, Orlowski RZ. Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737. PLoS One 9(9):e103015, 2014. e-Pub 9/2014. PMCID: PMC4151993.
10. Lu Y, Zhang M, Wang S, Hong B, Wang Z, Li H, Zheng Y, Yang J, Davis RE, Qian J, Hou J, Yi Q. p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression. Nat Commun 5:4229, 2014. e-Pub 6/2014. PMCID: PMC4249595.
11. Liu Z, Xu J, Li H, Zheng Y, He J, Liu H, Zhong Y, Lu Y, Hong B, Zhang M, Lin P, Du J, Hou J, Qian J, Kwak LW, Yi Q, Yang J. Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression. PLoS One 8(12):e82453, 12/2013. e-Pub 12/2013. PMCID: PMC3858321.
12. Zheng Y, Yang J, Qian J, Qiu P, Hanabuchi S, Lu Y, Wang Z, Liu Z, Li H, He J, Lin P, Weber D, Davis RE, Kwak L, Cai Z, Yi Q. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia 27(3):702-10, 3/2013. e-Pub 9/2012. PMCID: PMC3652581.
13. He J, Liu Z, Zheng Y, Qian J, Li H, Lu Y, Xu J, Hong B, Zhang M, Lin P, Cai Z, Orlowski RZ, Kwak LW, Yi Q, Yang J. p38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction. Cancer Res 72(24):6393-402, 12/2012. e-Pub 10/2012. PMCID: PMC3525770.
14. Zhang L, Yang J, Qian J, Li H, Romaguera JE, Kwak LW, Wang M, Yi Q. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood 120(18):3783-92, 11/2012. e-Pub 9/2012. PMCID: PMC3488890.
15. Lu Y, Hong S, Li H, Park J, Hong B, Wang L, Zheng Y, Liu Z, Xu J, He J, Yang J, Qian J, Yi Q. The helper 9 cells promote antitumor immune responses in vivo. J Clin Invest 122(11):4160-71, 11/2012. e-Pub 10/2012. PMCID: PMC3484462.
16. Yang J, He J, Wang J, Cao Y, Ling J, Qian J, Lu Y, Li H, Zheng Y, Lan Y, Hong S, Matthews J, Starbuck MW, Navone NM, Orlowski RZ, Lin P, Kwak LW, Yi Q. Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia 26(9):2114-23, 9/2012. e-Pub 3/2012. PMCID: PMC3381862.
17. Cao Y, Lan Y, Qian J, Zheng Y, Hong S, Li H, Wang M, Kwak LW, Lin D, Yang J, Yi Q. Targeting cell surface β2 -microglobulin by pentameric IgM antibodies. Br J Haematol 154(1):111-21, 7/2011. e-Pub 5/2011. PMCID: PMC3111817.
18. Li H, Hong S, Qian J, Zheng Y, Yang J, Yi Q. Crosstalk between the Bone and Immune systems: Osteoclasts Function as Antigen-Presenting Cells and Activate CD4+ and CD8+ T cells. Blood 116(2):210-7, 7/2010. e-Pub 3/2010. PMCID: PMC2910608.
19. Yang J and Yi Q. Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules. Cancer 116(7):1638-45, 4/2010. PMCID: PMC2847067.
20. Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, Li H, Wang M, Yang J, Yi Q. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 114(17):3625-8, 10/2009. e-Pub 8/2009. PMCID: PMC2766678.
21. Yang J, Cao Y, Hong S, Li H, QianJ, Kwak LW, and Yi Q. Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma. Clin Cancer Res 15(3):951-9, 2/2009. PMCID: PMC2659684.
22. Yang J, Zhang X, Wang J, Qian J, Zhang L, Wang M, Kwak LW, Yi Q. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood 110(8):3028-35, 10/2007. e-Pub 7/2007. PMCID: PMC2018676.
23. Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J, Wan B, Kwak LW, Yu L, Yi Q. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 12(3):252-65, 9/2007. PMID: 17785206.
24. Yang J, Qian J, Wezeman M, Wang S, Lin P, Wang M, Yaccoby S, Kwak LW, Barlogie B, Yi Q. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell 10(4):295-307, 10/2006. PMID: 17045207.

Invited Articles

1. Liu H, He J, Yang J. Tumor cell p38 MAPK: A trigger of cancer bone osteolysis. Cancer Cell Microenviron 2(1), 1/2015. PMCID: PMC4448135.

Book Chapters

1. Lu Y, Yang J and Yi Q. Signaling of Tumor-Induced Immunosuppression of Dendritic Cells. In: The Tumor Immunoenviroment. Ed(s) Shuin MR, Umansky V, Mayguine A. Springer: Netherlands, 2013.
2. Yang J and Yi Q. Signaling pathways mediating dendritic cells dysfunction in cancer. In: Dendritic Cells in Cancer. Ed(s) Shurin M and Salter R. Springer, 2009. ISBN: 978-0-387-88610-7.

Grant & Contract Support

Title: Role of integrin VLA-6 in suppression of bone formation in myeloma
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2/1/2016 - 1/31/2021
Title: A Novel Therapeutic Target for Myeloma Bone Destruction
Funding Source: American Cancer Society (ACS)
Role: Principal Investigator
Duration: 7/1/2015 - 6/30/2019
Title: Targeting adipocyte-secreted chemerin for chemotherapy resistance in myeloma
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 4/1/2015 - 3/30/2020
Title: MD Anderson Cancer Center SPORE in Multiple Myeloma Animal Core Facility
Funding Source: NIH/NCI
Role: Core Leader
Principal Investigator: Robert Z. Orlowski
Duration: 7/1/2012 - 6/30/2015

Last updated: 8/29/2016